Mer­ck­'s Keytru­da-chemo re­duces risk of death from bil­iary tract can­cer by 17%: #AACR23

OR­LAN­DO — Mer­ck’s Keytru­da racked up an­oth­er po­ten­tial win on Sun­day, show­ing pos­i­tive re­sults as a first-line treat­ment for ad­vanced bil­iary tract can­cers, for which there are few good op­tions.

The 1,069-pa­tient tri­al in metasta­t­ic or un­re­sectable bil­iary tract can­cers showed that pa­tients in the Keytru­da-chemo arm had a me­di­an over­all sur­vival of 12.7 months, com­pared with 10.9 months in those tak­ing a place­bo plus chemo. Af­ter a me­di­an fol­low-up of 25.6 months, pa­tients treat­ed with Keytru­da (al­so known as pem­brolizum­ab) had a 17% low­er risk of death than pa­tients who re­ceived just chemother­a­py. The re­sults were sta­tis­ti­cal­ly sig­nif­i­cant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.